X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Recognizing National Glaucoma Awareness Month

By Matthew Norawong  |    February 1, 2023
January was National Glaucoma Awareness Month and provided us an opportunity to spread the word and honor the millions of patients around the world who are impacted by this debilitating disease.   ...   Read More

Novel medicines approved in 2022 offer increased treatment options for patients

By Andrew Powaleny  |    January 23, 2023
2022 marked another year of significant progress by biopharmaceutical research companies conducting lifesaving research and development for innovative medicines with a total of 45 new medicine...   Read More

ICYMI: New approvals by the FDA in 2021 offer greater treatment options for patients

By Richard Moscicki, M.D.  |    January 26, 2022
The U.S. Food and Drug Administration (FDA) approved a total of 60 new drugs in 2021. A new report from the FDA catalogs 50 new approvals by the Center for Drug Evaluation and Research (CDER)....   Read More

3 things that support robust biopharmaceutical research and development

By Richard Moscicki, M.D.  |    June 29, 2021
Rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, many of the most challenging diseases, including cancer, rare...   Read More

New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections, but future pipeline remains challenging

By Andrew Powaleny  |    April 29, 2021
The discovery and introduction of antibiotics in the 1940s transformed modern medicine and enabled tremendous progress in health care and life expectancy. Today, this progress is being threatened by...   Read More

ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures

By Andrew Powaleny  |    April 12, 2021
America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. The ongoing...   Read More

Lessons learned from COVID-19: The way we develop new medicines is changing

By Richard Moscicki, M.D.  |    February 10, 2021
The COVID-19 pandemic has affected nearly every aspect of society, including the way scientists conduct the testing of medicines.   Read More

2020 FDA approvals show innovation despite COVID-19 pandemic challenges

By Andrew Powaleny  |    January 26, 2021
A new report from the U.S. Food and Drug Administration (FDA) notes that the Center for Drug Evaluation and Research (CDER) approved 53 novel drugs last year. These figures are in addition to...   Read More

ICYMI: Cancer death rate continues decline due to advances in treatment

By Andrew Powaleny  |    January 19, 2021
For the second year in a row, The American Cancer Society (ACS) reports a record single-year decline in cancer death rates in the United States. Each year, ACS estimates the number of new cancer...   Read More

Report: More than 1,300 medicines and vaccines in development to help fight cancer

By Andrew Powaleny  |    December 15, 2020
Over the last 30 years, significant progress has been made in the fight against cancer. Researchers have expanded their understanding of how cancer develops and how to target medicines for specific...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates